Solventum (NYSE:SOLV) Given New $95.00 Price Target at Wells Fargo & Company

Solventum (NYSE:SOLV) had its target price hoisted by Wells Fargo & Company from $89.00 to $95.00 in a research note issued to investors on Friday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

Several other research analysts have also issued reports on SOLV. Wedbush boosted their target price on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. BTIG Research reiterated a “buy” rating on shares of Solventum in a report on Friday. Stifel Nicolaus increased their price target on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Piper Sandler reissued an “overweight” rating and set a $110.00 price target (up from $105.00) on shares of Solventum in a research note on Friday. Finally, Canadian Imperial Bank of Commerce set a $35.00 price objective on Solventum in a report on Wednesday, October 28th. Ten equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $90.27.

Solventum Trading Up 3.6%

Shares of SOLV stock traded up $3.17 during trading hours on Friday, reaching $90.34. 3,168,921 shares of the stock were exchanged, compared to its average volume of 1,109,088. Solventum has a 12-month low of $62.38 and a 12-month high of $94.16. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The company’s 50-day moving average price is $87.73 and its 200-day moving average price is $78.70. The firm has a market capitalization of $15.38 billion, a price-to-earnings ratio of 101.51, a price-to-earnings-growth ratio of 1.24 and a beta of 0.69.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, November 5th. The company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.34 by $0.11. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same period in the prior year, the firm posted $1.50 EPS. The firm’s revenue was down 7.0% compared to the same quarter last year. As a group, equities analysts anticipate that Solventum will post 7.21 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Diamond Hill Capital Management LLC Investment Advisor bought a new stake in Solventum during the 2nd quarter valued at about $150,066,000. Bank of New York Mellon Corp bought a new position in Solventum in the 2nd quarter worth about $61,460,000. Assenagon Asset Management S.A. grew its stake in Solventum by 16,656.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 482,930 shares of the company’s stock worth $42,570,000 after acquiring an additional 480,048 shares in the last quarter. Squarepoint Ops LLC grew its stake in Solventum by 6,103.8% in the 2nd quarter. Squarepoint Ops LLC now owns 243,128 shares of the company’s stock worth $18,757,000 after acquiring an additional 239,209 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Solventum by 44.0% during the first quarter. Dimensional Fund Advisors LP now owns 774,683 shares of the company’s stock worth $50,576,000 after acquiring an additional 236,659 shares during the period.

Solventum News Summary

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Solventum earned $1.45 per share on $1.95 billion in revenue, beating consensus estimates of $1.34–$1.35 per share and $1.93 billion in sales. The company raised its 2026 adjusted EPS guidance to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Q3 results
• Positive Sentiment: Analysts lifted price targets: Piper Sandler raised its target to $110 and reaffirmed an overweight rating; Wells Fargo increased its target to $95 while retaining an equal-weight rating. Jefferies raised its target to $98. Piper Sandler rating
• Neutral Sentiment: The company said the 7% year-over-year sales decline (organic sales down 2.8%) reflected, in part, a temporary ERP transition effect: customers had placed advance orders in the prior quarter ahead of the system cutover. Solventum also reported that its separation process was more than 90% complete. Q3 earnings and ERP impact
• Negative Sentiment: Despite the quarterly beat, revenue fell 7% year over year and EPS was down from $1.50 a year ago, highlighting ongoing comparisons and execution risks. Quarterly earnings details

About Solventum

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.